NEW YORK, August 23, 2018 – The global NASH market is projected to reach $21.5 billion by 2025, with NASH being the leading cause of liver transplantation in the US in the coming years. 1 The NASH Network (NASHNET), in collaboration with The Kinetix Group, has launched a Real World Evidence study to optimize care delivery for patients with Non-Alcoholic Steatohepatitis (NASH). This initiative is in partnership with Echosens, the innovators and marketers of the FibroScan® family of products.